<DOC>
	<DOCNO>NCT02443402</DOCNO>
	<brief_summary>The purpose study compare sitagliptin placebo prevention high blood glucose surgery .</brief_summary>
	<brief_title>Sitagliptin Non-Diabetic Patients Undergoing Cardiac Surgery</brief_title>
	<detailed_description>About 80 % patient develop high glucose cardiac surgery . High glucose link increase risk hospital complication . High glucose increase risk wound infection , kidney failure death . Patients high glucose treated insulin give arm vein frequent insulin injection skin . This study determine sitagliptin prevent development high glucose heart surgery . Sitagliptin diabetes pill approve Food Drug Administration ( FDA ) treat patient diabetes .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Males female age 18 80 year undergoing , cardiac surgery No previous history diabetes No previous history hyperglycemia Patients hyperglycemia ( blood glucose &gt; 125 mg/dL ) ; glycated hemoglobin ( HbA1c ) &gt; 6.5 % ; previous treatment oral antidiabetic agent insulin Severely impaired renal function ( serum creatinine â‰¥3.0 mg/dL GFR &lt; 30 mL/min ) clinically significant hepatic failure Moribund patient imminent risk death ( brain death cardiac standstill ) Subjects gastrointestinal ( GI ) obstruction adynamic ileus expect require GI suction Patients clinically relevant pancreatic gallbladder disease Treatment oral injectable corticosteroid Mental condition render subject unable understand scope , consequence study Female subject pregnant breast feeding time enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non diabetic hyperglycemia</keyword>
</DOC>